| | Price Trend | Performance | Ratios | Snapshot

Sun Pharmaceutical Industries | 72.94% [Reasonable Score] |Shares Pledge: [1.97%]

Is the company worth investing in (now)?: I'll Wait Longer To Build Better Margin of Safety [Price Must Correct But Fundamentals are OK]

1,954.15

14.00 | 0.72%

Price

Healthcare - Branded Medicines

1,384.03

Overvalued

Intrinsic Value

Top | Performance | Ratios | Snapshot

Price Trend

4%
Price 14 Day

Past → Today

8%
Price 30 Day

Past → Today

15%
Price 90 Day

Past → Today

Overview
How is the Stock? Price: Looks Overvalued & Fundamentals Only Reasonable
Overall Score (Remark) 72.94% [Reasonable Score] |Shares Pledge: [1.97%]
Is It A Fundamentally Strong Company? Fundamentals Only Reasonable
Fundamental Strength Score [out of 5] 3.18
Overview
8.78%
Last 10Y Price Trend

Past → Today

-1.74%
P/E

Past → Today

Quick Observations #1
  1. The operating revenue has grown consistently in the last 5 years
  2. Positive @8.63% p.a. in the last 5 years
  3. Reasonably consistent in the last 5 years
  4. Maintained a positive EBITDA Margin of 29.11% in the last 5 years
  5. EBITDA Margin has improved in the last 5 years @12.51% p.a.
Quick Observations #2
  1. Reasonably consistent in the last 5 years
  2. Maintained a positive PAT Margin of 19.19% in the last 5 years
  3. PAT Margin has improved in the last 5 years @17.16% p.a.
  4. Reasonably consistent in the last 5 years
  5. Maintained a positive ROE of 14.5% in the last 5 years
  6. ROE has improved in the last 5 years @14.13% p.a.
Quick Observations #3
  1. Total asset has grown at 9.28% p.a. in the last 5 Years
  2. The company has been consistently solvent in the last 5 years
  3. The D/E ratio of the company has remained stable in the last 5 years
  4. Maintained an average D/E ratio of 0.05 in the last 5 years
Quick Observations #4
  1. Consistently liquid in the last 5 years
  2. Improved in the last 5 years
  3. Maintained an average current ratio of 2.7 in the last 5 years
  4. Consistently Positive
Price Valuation
Is It An Undervalued Stock? Looks Overvalued
Price Valuation Score [out of 5] 2.83
Price ₹1,954.15
Intrinsic Value ₹1,384.03
P/E 40.77
EV/EBITDA 24.81
P/FCF 131.82
Current Price vs. Intrinsic Value (IV)
Current Price

₹1,954.15

Intrinsic Value

₹1,384.031

Overvalued

Sample Data. Subscribe to view actual data.
Share Holding Pattern
Profitability
Is It A Profitable Company? Highly Profitable
Profitability Score [out of 5] 4.35
WAAC 13.30%
ROCE-5Y 16.01%
Free Cash Flow Positive
Operating Profit 13,681.00
Net Profit 11,477.00
Profitability
Growth
Is It A Growing Company? Growth Rate Is Above Average
Growth Score [out of 5] 3.50
Reserves Growth 12.00%
Total Asset Growth 9.00%
Operating Revenue Growth 9.00%
Net Profit Growth 28.00%
Operating Cash Flow Growth 7.00%
FCF Growth (5Y) 15.00%
Sustainable Growth 11.00%
24.96%
EPS

Past → Today

Financial Health
Is The Company Financially Healthy? Financial Health Is Average
Financial Health Score [out of 5] 3.52
Is the company liquid? Yes. Its Liquidity is Very High
Is the ROE growing? No. The Trend is Falling
Is the ROE high? Yes. Its High
Company is reducing debt? No. D/E Ratio is Growing V.Fast
Company's D/E ratio is low? Yes. D/E Ratio is Very Low
Is the ROCE growing? No. It is Falling
Is the ROCE High? Yes. It is High
Financial Health
Quality of Management
How Is The Quality Of The Management? Management Quality Is Reasonably
Management Quality Score [out of 5] 3.99
Operating profit is Growing? Yes. The Operating Profit has grown
Operating profit Consistently Growing? No. The Operating Profit Growth in not Consistent
EPS is Growing? Yes. The EPS has grown
EPS Consistently Growing? No. The EPS Growth in not Consistent
Capital Utilization is Proper? No. Capital Use Needs Improvement
Reinvested Capital Meets The Purpose? Yes. But it only Modest
Is It Overpaying The Dividends? Yes. It can Afford, But it can consdier Reinvestment
Operating Profit Margin
Competitive Moat
Does The Company Has Competitive Moat? Moat Is Only Reasonably Wide
Moat Score [out of 5] 3.72
Competitors
NameM.Cap (₹ Cr.)Revenue (₹ Cr.)PAT (₹ Cr.)TTM EPSTTM P/EP/BROEOverall Score (%)
Cipla116,273.9729,044.603,869.7948.0429.933.3811.26Subscribe to view
Lupin114,043.4828,382.485,355.47116.7621.381,875.418,766.65Subscribe to view
Torrent Pharmaceuticals168,748.8313,886.152,138.1863.9277.9120.1225.79Subscribe to view
Sun Pharmaceutical Industries468,685.9160,433.7611,564.5247.8040.885.6113.73Subscribe to view
Zydus Lifesciences115,760.2827,657.905,026.4050.1023.044.2718.58Subscribe to view
Theme Ranks
Theme Rank Total Stocks Theme Rank Total Stocks
Best Stocks 90 995 Fast Growing Stocks 251 1,001
Profitable Stocks 22 984 Dividend Paying Stocks 28 385
Blue-Chip Stocks 3 81 Low PE Stocks 107 113
Debt Free Stocks 6 641 Buffet Type Stocks 140 1,001
Fundamentally Strong Stocks 193 1,001 High Return Stocks 258 1,367
Undervalued Stocks 353 1,000 Penny Stocks 0 102
Profitable & Growing Stocks 0 122
Price Summary
Today's High Today's Low 52W High 52W Low
1,962.5 1,944.85 1,962.5 1,547.25
Recent Results
Market Cap (Cr) Revenue (Cr) Net Profit (Cr) Net Worth (Cr)
467,870.13 60,433.76 11,564.52 83,570.09
D/E Current Ratio ROE (%) ROCE (%)
0.05 2.82 13.73 18.16
Valuation & Growth
P/E P/B Div.Yield (%) PEG (%)
40.77 5.61 0.87 23.97
EPSG-3Y (%) EPSG-3Y (%) 3M-Return (%) 1Y-Return (%)
8.43 24.96 7.96 15.17
About Company

Sun Pharmaceutical Industries Ltd. is the fifth largest speciality generic pharmaceutical company in the world. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics branded generics complex or difficult to make technology intensive products over-the-counter (OTC) products anti-retrovirals (ARVs) Active Pharmaceutical Ingredients (APIs) and intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage forms including tablets capsules injectables inhalers ointments creams and liquids. The products cater to a vast range of therapeutic segments covering psychiatry anti-infectives neurology cardiology orthopaedic diabetology gastroenterology ophthalmology nephrology urology dermatology gynaecology respiratory oncology dental and nutritionals.

Top | Price Trend | Ratios | Snapshot

Performance Summary

5.9%

Net Sales

Past → Today

6.3%

Total Income

Past → Today

8.87%

Operating Profit

Past → Today

6.04%

PAT

Past → Today

8.34%

Net Worth

Past → Today

6.43%

EPS

Past → Today

4%

Last 14D Price Trend

Past → Today

8%

Last 30D Price Trend

Past → Today

15%

Last 90D Price Trend

Past → Today

17%

Last 180D Price Trend

Past → Today

15%

Last 1Y Price Trend

Past → Today

22.14%

Last 3Y Price Trend

Past → Today

23.95%

Last 5Y Price Trend

Past → Today

0%

EV/EBIDTA

Past → Today

Top | Price Trend | Performance | Snapshot

Ratios

Liquidity Ratios
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
Current Ratio-2.822.822.892.562.002.04
Quick Ratio-2.322.322.331.981.481.51
Cash Ratio-0.510.510.620.620.290.29
Solvency Ratios
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
Current Debt to Inventory-1.971.971.781.721.891.91
Current Debt to Equity-0.050.050.030.040.110.02
D / E-0.050.050.030.040.110.02
Interest Coverage Ratio-46.5845.6160.4447.5055.7036.19
Efficiency Ratios
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
Fixed Asset Turnover Ratio-2.242.252.592.432.122.25
Gross Margin%80.2580.2579.5678.0175.7073.22
Operating Margin%23.4023.0722.8620.5620.389.54
EBITDA Margin%30.7630.4430.3627.8527.2017.06
PAT Margin%18.9919.1420.1319.3519.238.61
Op.Cash Flow Margin%21.2421.2426.7625.0211.3023.24
ROA%10.5510.6311.9211.2910.604.88
ROE%13.7313.8415.2015.1515.297.09
ROCE%18.1617.9418.9216.5415.758.76
ROIC%7.938.179.6510.4210.413.13
Price Valuation Ratios
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
P/E-40.8038.0942.8329.4871.5252.67
PEG-23.978.322.351.720.1752.67
EV/EBITDA-24.7622.3222.7916.5318.5120.92
Price to Sales-8.017.157.364.895.103.76
P/B-5.605.005.363.724.003.03
Dividend Yield%0.840.940.931.221.131.49
P/FCF-82.1673.36105.3029.8018.17-13.54
FCF/Sales-0.040.040.070.030.02-0.02
Earnings Yield%3.403.763.714.944.273.26
Top | Price Trend | Performance | Ratios

Snapshot

Quarterly Report
IndicatorUnitTTMMar '26Dec '25Sep '25Jun '25Mar '25
SalesRs. Cr.58,460.0014,611.0015,520.0014,478.0013,851.0012,958.00
Other IncomeRs. Cr.1,969.00458.00578.00469.00464.00612.00
Op. ProfitRs. Cr.14,792.003,178.004,216.003,797.003,601.003,052.00
EBITDARs. Cr.18,586.0018,395.6416,558.8813,883.0012,109.866,752.41
PBTRs. Cr.15,401.003,514.004,548.004,167.003,172.003,254.00
PATRs. Cr.11,477.002,714.003,368.003,117.002,278.002,149.00
EPSRs. Cr.47.8011.3014.0013.009.509.00
Profit & Loss Account
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
IncomeRs. Cr.60,429.0060,433.7654,543.4849,851.0444,520.2039,576.00
ExpenseRs. Cr.44,007.4044,007.4040,113.5038,268.8334,940.3230,527.86
Op.ProfitRs. Cr.13,681.0013,486.0712,018.459,972.178,945.913,687.16
EBITDARs. Cr.18,586.0018,395.6416,558.8813,883.0012,109.866,752.41
PBTRs. Cr.15,401.003,514.004,548.004,167.003,172.003,254.00
PATRs. Cr.11,477.002,714.003,368.003,117.002,278.002,149.00
EPSRs. Cr.47.8011.3014.0013.009.509.00
DividendRs. Cr.3,933.903,933.903,613.972,898.162,519.302,158.91
Balance Sheet
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
Share CapitalRs. Cr.239.93239.93239.93239.93239.93239.93
ReservesRs. Cr.83,330.1683,330.1671,978.0963,426.8255,755.4547,771.29
Net WorthRs. Cr.83,570.0983,570.0972,218.0263,666.7555,995.3848,011.22
ST BorrowingsRs. Cr.4,050.354,050.351,867.112,844.366,197.88700.77
LT BorrowingsRs. Cr.31.2631.262.521.330.00229.92
Fixed AssetsRs. Cr.26,040.9226,040.9220,290.8219,966.3120,680.5717,197.09
Current LiabilitiesRs. Cr.22,622.0422,622.0418,194.2116,984.4019,907.0017,200.55
CashRs. Cr.11,603.0811,603.0811,331.6210,520.685,770.295,033.35
Current AssetsRs. Cr.63,891.1963,891.1952,624.4743,474.9839,883.3435,014.98
Total AssetsRs. Cr.108,785.22108,785.2292,100.5885,462.8880,743.5969,799.87
Cash Flow Report
IndicatorUnitTTMMar 26Mar 25Mar 24Mar 23Mar 22
Net Cash From Oprn.Rs. Cr.12,419.1812,419.1814,072.0912,134.984,959.338,984.54
Net Cash From InvestingRs. Cr.-11,344.05-11,344.05-5,306.16-690.20-7,943.68-5,724.74
Net Cash From FinancingRs. Cr.-2,512.55-2,512.55-7,905.82-6,710.162,376.07-5,193.46